SCHEDULE: Morgan Stanley Discloses 6.0% Stake in PROKIDNEY CORP.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have reported a 6.0% beneficial ownership stake in PROKIDNEY CORP.'s Class A Common Stock.

Summary

• Morgan Stanley and Morgan Stanley Investment Management Inc. (MSIM Inc.) have filed a Schedule 13G, disclosing their beneficial ownership in PROKIDNEY CORP.
• As of December 31, 2025, Morgan Stanley beneficially owned an aggregate of 8,519,982 shares of Class A Common Stock, representing 6.0% of the class.
• Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley, beneficially owned 8,518,684 shares, also representing 6.0% of the class.
• Both entities reported having shared voting power over approximately 8.25 million shares and shared dispositive power over approximately 8.52 million shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PROKIDNEY CORP.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While a 13G is a factual disclosure, a significant institutional stake from a reputable firm like Morgan Stanley can be interpreted as a vote of confidence in PROKIDNEY CORP.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes by major financial institutions. Morgan Stanley's disclosure of a 6.0% stake in PROKIDNEY CORP. indicates a notable institutional interest in the company, which can be a positive signal for other investors, suggesting confidence in the company's long-term prospects or current valuation.

Comparison to Industry Standards

• This filing is a standard disclosure for institutional investors like Morgan Stanley when their beneficial ownership in a public company exceeds 5% of a class of securities, as mandated by SEC Rule 13d-1(b).
• The reported 6.0% stake is a significant position for a single institutional investor, comparable to holdings seen by major asset managers in other biotechnology or pharmaceutical companies at similar stages of development.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 6.0% stake may increase investor confidence and potentially attract further institutional interest, positively impacting share price.
• Company Management: Awareness of a major institutional holder may influence strategic decisions, though the filing explicitly states the stake is not for control purposes.

Key Dates

Keywords

PROKIDNEY CORP, Morgan Stanley, Morgan Stanley Investment Management, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Ownership, SEC Filing